You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Relmacabtagene Autoleucel Injection
  • (no location specified)
Apr 13, 2023

Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Amyloid Light-chain Amyloidosis
  • (no location specified)
Apr 20, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed/Refractory Large B-cell Lymphoma
  • (no location specified)
Oct 6, 2023

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Mar 6, 2023

Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 15, 2023

Refractory/Relapsed Autoimmune Hemolytic Anemia Trial in Tianjin (Zanubrutinib)

Not yet recruiting
  • Refractory/Relapsed Autoimmune Hemolytic Anemia
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
Aug 27, 2023

Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer Trial in Santa Monica

Not yet recruiting
  • Pathologically Confirmed Cancer Refractory to Conventional Therapy
  • +7 more
  • SNK02
  • Santa Monica, California
    Sarcoma Oncology Center
Aug 10, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for

Completed
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Relapsed or Refractory Multiple Myeloma
  • BEBT-908 for injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 9, 2023

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride

Not yet recruiting
  • Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
  • Anlotinib Hydrochloride Capsule and Penpulimab
  • Beijing, Beijing, China
    YansongLin
Sep 25, 2023

Refractory Chronic Cough Trial (Nalbuphine Hydrochloride, Placebo)

Not yet recruiting
  • Refractory Chronic Cough
  • Nalbuphine Hydrochloride
  • Placebo
  • (no location specified)
Jul 18, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Acute Myeloid Leukemia Trial (Dasatinib)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 20, 2023

Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 2001
  • Benowa, Queensland, Australia
    Pindara Private Hospital
May 18, 2023

Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)

Not yet recruiting
  • Acute Myeloid Leukemia
  • MCBC regimen
  • Bu/Cy regimen
  • (no location specified)
Nov 13, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • YTS104 Cells injection
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 13, 2023

Relapsed or Refractory Lymphomas, Advanced Solid Tumor Trial in Los Alamitos (LP-284)

Not yet recruiting
  • Relapsed or Refractory Lymphomas
  • Advanced Solid Tumor
  • Los Alamitos, California
    Cancer and Blood Specialty Clinic
Nov 9, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Refractory Pain Trial in Spain

Recruiting
  • Refractory Pain
    • Málaga, Andalucia, Spain
    • +4 more
    Aug 1, 2023